Company: REVB
Filing Date: 2025-05-20
Form Type: S-1
Source: 0001213900-25-045828
Chunk: 9

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-20
Form: S-1
Chunk 9
---
 Related to Our Business

| ● | We have a limited operating history and no products approved                                                                          
 for commercial sale. We have incurred net losses since our inception, we anticipate that we will continue to incur significant losses 
 for the foreseeable future, and even if we were to generate revenue, we may never achieve or maintain profitability.                  |

Risks Related to the Product Development, Regulatory Approval, Manufacturing and Commercialization of Our Program Products and Product Candidates

| ● | If preclinical studies or clinical studies for our Program                                    
 Products are unsuccessful or delayed, we will be unable to meet our future development goals. |

| ● | The results of prior preclinical or clinical studies are 
 not necessarily predictive of our future results.        |

| ● | The Clinical Studies of our Program Products’ have                                                                              
 been and may in the future be conducted outside the United States, and the FDA or comparable foreign regulatory authorities may 
 not accept data from such studies.                                                                                              |

| ● | Our Program Products and the administration of our Program                                                                            
 Products may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the 
 commercial profile of an approved label or result in significant negative consequences following marketing approval, if any.          |

| ● | Our business depends on the success of our Program Products,                                                                     
 including obtaining regulatory approval to market our Product Candidates in the United States and/or other major foreign markets 
 such as the European Union.                                                                                                      |

| ● | Even if we obtain regulatory approval for a product candidate,                              
 our products and business will remain subject to ongoing regulatory obligations and review. |

| ● | Legislative or regulatory healthcare reforms in the United States                                                                      
 or other countries may make it more difficult and costly for us to obtain regulatory clearance or approval of our Program Products and 
 to produce, market and distribute our Program Products after clearance or approval is obtained.                                        |

| ● | We face intense competition in an environment of rapid technological                                                                        
 change and the possibility that our competitors may develop products and drug delivery systems that are similar, more advanced or more      
 effective than ours, which may adversely affect our financial condition and our ability to successfully market or commercialize our Program 
 Products.                                                                                                                                   |

5

Risks Related to our Reliance on Third Parties

| ● | We rely on third parties to conduct certain elements of our                                                                                   
 preclinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual       
 duties, meet expected deadlines or comply with regulatory requirements,